Evaluation of transforming growth factor-beta 1 concentrations in serum, peritoneal and endometrioma fluid in women operated on for ovarian endometriosis as a biomarker of endometrioma.

Ginekologia polska Pub Date : 2025-05-26 DOI:10.5603/gpl.97117

Mariusz Wojtowicz, Dariusz Zdun, Aleksander J Owczarek, Violetta Skrzypulec-Plinta, Magdalena Olszanecka-Glinianowicz

{"title":"Evaluation of transforming growth factor-beta 1 concentrations in serum, peritoneal and endometrioma fluid in women operated on for ovarian endometriosis as a biomarker of endometrioma.","authors":"Mariusz Wojtowicz, Dariusz Zdun, Aleksander J Owczarek, Violetta Skrzypulec-Plinta, Magdalena Olszanecka-Glinianowicz","doi":"10.5603/gpl.97117","DOIUrl":null,"url":null,"abstract":"Objectives: Some studies indicate the role of transforming growth factor-beta 1 (TGF-beta 1) in the development of endometriosis. However, the lack is studies assessed its plasma levels as a biomarker of endometrioma. Therefore, this study aimed to analyze plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations in women operated on for ovarian endometriosis.Material and methods: A cross-sectional cohort study involved 56 women operated on for ovarian endometriosis. Body mass, height, and waist circumference were measured, as well as body mass index (BMI) being calculated. Plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA).Results: Levels TGF-beta 1 were significantly higher in plasma than in both fluids (1286.1 pg/mL vs 114.7 pg/mL; p < 0.001 and 114.7 pg/mL vs 33.6 pg/mL; p < 0.001) and in endometrioma fluid than in peritoneal fluid (114.7 pg/mL vs 33.6 pg/mL; p < 0.001). There were also positive correlations between TGF-beta 1 levels in endometrioma and peritoneal fluids and plasma (r = 0.46; p < 0.001; r = 0.30; p < 0.05, respectively). There were no associations between TGF-beta 1 in plasma, endometrioma, peritoneal fluid, and endometriosis stage.Conclusions: Our results suggest that plasma TGF-beta 1 concentration can be considered as a biomarker of endometrioma.","PeriodicalId":94021,"journal":{"name":"Ginekologia polska","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ginekologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/gpl.97117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Some studies indicate the role of transforming growth factor-beta 1 (TGF-beta 1) in the development of endometriosis. However, the lack is studies assessed its plasma levels as a biomarker of endometrioma. Therefore, this study aimed to analyze plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations in women operated on for ovarian endometriosis.

Material and methods: A cross-sectional cohort study involved 56 women operated on for ovarian endometriosis. Body mass, height, and waist circumference were measured, as well as body mass index (BMI) being calculated. Plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA).

Results: Levels TGF-beta 1 were significantly higher in plasma than in both fluids (1286.1 pg/mL vs 114.7 pg/mL; p < 0.001 and 114.7 pg/mL vs 33.6 pg/mL; p < 0.001) and in endometrioma fluid than in peritoneal fluid (114.7 pg/mL vs 33.6 pg/mL; p < 0.001). There were also positive correlations between TGF-beta 1 levels in endometrioma and peritoneal fluids and plasma (r = 0.46; p < 0.001; r = 0.30; p < 0.05, respectively). There were no associations between TGF-beta 1 in plasma, endometrioma, peritoneal fluid, and endometriosis stage.

Conclusions: Our results suggest that plasma TGF-beta 1 concentration can be considered as a biomarker of endometrioma.

查看原文本刊更多论文

卵巢子宫内膜异位症手术妇女血清、腹膜和子宫内膜异位症液中转化生长因子- β 1浓度作为子宫内膜异位症的生物标志物的评估

目的：一些研究表明转化生长因子- β 1 （tgf - β 1）在子宫内膜异位症发生中的作用。然而，缺乏评估其血浆水平作为子宫内膜瘤生物标志物的研究。因此，本研究旨在分析卵巢子宫内膜异位症手术女性的血浆、腹膜和子宫内膜异位症液tgf - β 1浓度。材料和方法：一项横断面队列研究涉及56名卵巢子宫内膜异位症手术妇女。测量了体重、身高和腰围，并计算了身体质量指数（BMI）。采用酶联免疫吸附试验（ELISA）测定血浆、腹膜和子宫内膜瘤液tgf - β 1浓度。结果：血浆中tgf - β 1水平显著高于两种液体(1286.1 pg/mL vs 114.7 pg/mL；p < 0.001和114.7 pg/mL vs 33.6 pg/mL；p < 0.001)，子宫内膜瘤液比腹膜液(114.7 pg/mL vs 33.6 pg/mL；P < 0.001)。子宫内膜瘤中tgf - β 1水平与腹膜液和血浆之间也存在正相关(r = 0.46；P < 0.001；R = 0.30；P < 0.05)。tgf - β 1在血浆、子宫内膜异位症、腹膜液和子宫内膜异位症分期之间没有相关性。结论：我们的研究结果提示血浆tgf - β 1浓度可被认为是子宫内膜异位瘤的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ginekologia polska

自引率

0.00%

发文量